Hero LOQTORZI Solutions™

FINANCIAL SUPPORT IS AVAILABLE

LOQTORZI Solutions™, part of the Coherus Solutions™ family of support services, offers a range of patient support programs for patients who are prescribed LOQTORZI™

Helpful resources

$0Co-pay savings program

Coherus’s LOQTORZI™ Co-Pay Savings Program may cover a portion of out-of-pocket costs associated with LOQTORZI™ for eligible patients with commercial insurance.

Under the program, assistance with drug co-pay costs is available up to $30,000 per calendar year. Eligible patients could pay as little as $0 per dose of LOQTORZI™.

Patient eligibility criteria

  • Be prescribed LOQTORZI™ for a medically appropriate purpose within 180 days of program enrollment
  • Have commercial (private or nongovernmental) health insurance that covers the medication costs of LOQTORZI™
  • Over the age of 18 years old and a US resident
  • Not covered by any federal, state, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Veterans Affairs, Department of Defense, or TRICARE
  • Not seek reimbursement from any third party, including payers, charitable foundation, or flexible spending accounts (FSAs) or healthcare savings accounts (HSAs) for all or any of the benefit received by Coherus through the program
  • Other restrictions apply; see Terms and Conditions at LOQTORZISolutions.com
  • It is not valid for cash-paying patients or where prohibited by law
  • LOQTORZI™ Co-Pay Savings Program is subject to change or discontinuation without notice

Assistance programPatient assistance program

LOQTORZI™ may be available to you at no cost if you are uninsured, functionally underinsured,* or are a Medicare patient experiencing financial hardship.

Financial assistance eligibility criteria

  • Be either: (a) uninsured; (b) functionally underinsured*; or (c) traditional Medicare Fee-for-Service (FFS) insured patient(s) who demonstrate financial hardship and cannot afford their cost-sharing obligation as evidenced by a signed attestation from their provider
  • Have an adjusted annual household income of ≤500% of Federal Poverty Level (FPL)
  • Complete and sign consent form and, when applicable, provide income documentation
  • Be under the care of a US licensed provider, and receive LOQTORZI™ in an established practice located in the United States incident to the prescribing physician’s professional services in the outpatient setting
  • LOQTORZI Solutions™ may be able to assess patient eligibility for retrospective patient assistance. Please contact LOQTORZI Solutions™ at 1-844-483-3692 for additional information. Medicare patients are not eligible for retrospective patient assistance
  • If eligible, the Patient Assistance Program only covers the costs of LOQTORZI™ and does not cover any administration or office visit costs. Restrictions may apply, and the program is not valid where prohibited by law. Coherus may revise or terminate this program without notice at any time for any reason
  • Be a US resident
  • Diagnosis is for an FDA-approved indication of LOQTORZI™
  • Not have any other financial support options
  • The patient must receive the drug in an outpatient setting by the physician or physician office

*Functionally underinsured means the patient does not have insurance or has insurance by no coverage for LOQTORZI™.
For more financial or practice resources from LOQTORZI Solutions™, call 1-844-483-3692
Get more educational tools and resources to help support you on your treatment journey.
Learn about the possible side effects of LOQTORZI™ treatment.
See how LOQTORZI™ may give you the chance for more time without your cancer progressing.

INDICATIONS

LOQTORZI™ (toripalimab-tpzi) is a prescription medicine used to treat adults with a kind of cancer called nasopharyngeal carcinoma (NPC).

  • LOQTORZI™ may be used in combination with the chemotherapy medicines cisplatin and gemcitabine, as your first treatment when your NPC has spread to other parts of your body (metastatic) or has returned (recurrent) in nearby tissues (locally advanced).
  • LOQTORZI™ may be used alone to treat your NPC when it:
    • has returned (recurrent) and cannot be removed with surgery or
    • has spread (metastatic), and
    • you received chemotherapy that contains platinum, and it did not work or is no longer working.

It is not known if LOQTORZI™ is safe and effective in children.

Important Safety Information
What is the most important information I should know about LOQTORZI™?

LOQTORZI™ is a medicine to treat nasopharyngeal cancer by working with your immune system. LOQTORZI™ can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after treatment has ended.

INDICATIONS

LOQTORZI™ (toripalimab-tpzi) is a prescription medicine used to treat adults with a kind of cancer called nasopharyngeal carcinoma (NPC).

  • LOQTORZI™ may be used in combination with the chemotherapy medicines cisplatin and gemcitabine, as your first treatment when your NPC has spread to other parts of your body (metastatic) or has returned (recurrent) in nearby tissues (locally advanced).
  • LOQTORZI™ may be used alone to treat your NPC when it:
    • has returned (recurrent) and cannot be removed with surgery or
    • has spread (metastatic), and
    • you received chemotherapy that contains platinum, and it did not work or is no longer working.

It is not known if LOQTORZI™ is safe and effective in children.

Important Safety Information
What is the most important information I should know about LOQTORZI™?

LOQTORZI™ is a medicine to treat nasopharyngeal cancer by working with your immune system. LOQTORZI™ can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after treatment has ended.

Call or see your health care provider right away if you develop any signs or symptoms of the following problems or if they get worse, including:

  • Lung problems: cough, shortness of breath, or chest pain.
  • Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; severe stomach-area (abdomen) pain or tenderness.
  • Liver problems: yellowing of your skin or the whites of your eyes; severe nausea or vomiting; pain on the right side of your stomach area (abdomen); dark urine (tea colored); or bleeding or bruising more easily than normal.
  • Hormone gland problems: headaches that will not go away or unusual headaches; eye sensitivity to light; eye problems; rapid heartbeat; increased sweating; extreme tiredness; weight gain or weight loss; feeling more hungry or thirsty than usual; urinating more often than usual; hair loss; feeling cold; constipation; your voice gets deeper; dizziness or fainting; change in mood or behavior, such as decreased sex drive, irritability, or forgetfulness.
  • Kidney problems: decrease in your amount of urine; blood in your urine; swelling of your ankles; loss of appetite.
  • Skin problems: rash; itching; skin blistering or peeling; painful sores or ulcers in your mouth or in your nose, throat, or genital area; fever or flu-like symptoms; swollen lymph nodes.
  • Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with LOQTORZI™. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: chest pain, irregular heartbeat, shortness of breath, swelling of ankles; confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs; double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight; persistent or severe muscle pain or weakness, muscle cramps; low red blood cells, bruising.
  • Infusion reactions that can sometimes be severe or life-threatening. Signs or symptoms of infusion reactions may include: chills or shaking; itching or rash; flushing; shortness of breath or wheezing; dizziness; feeling like passing out; fever; back pain.
  • Rejection of a transplanted organ. Your healthcare provider should tell you what signs and symptoms you should report and monitor, depending on the type of organ transplant that you have had.
  • Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with LOQTORZI™. Your healthcare provider will monitor you for these complications.

Getting medical treatment right away may help keep these problems from becoming more serious.
Your healthcare provider will check you for these problems during treatment with LOQTORZI™. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with LOQTORZI™ if you have severe side effects.

Before you receive LOQTORZI™, tell your health care provider about all of your medical conditions, including if you:

  • have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
  • have received an organ transplant or have received or plan to receive a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic)
  • have received radiation treatment in your chest area
  • have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
  • are pregnant or plan to become pregnant. LOQTORZI™ can harm your unborn baby. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with LOQTORZI™. Use effective birth control during treatment and for at least 4 months after your final dose of LOQTORZI™. Tell your health care provider right away if you think you may be pregnant or you become pregnant during treatment with LOQTORZI™
  • are breastfeeding or plan to breastfeed. It is not known if LOQTORZI™ passes into your breast milk. Do not breastfeed during treatment with LOQTORZI™ and for 4 months after your final dose of LOQTORZI™

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the most common side effects of LOQTORZI™?

  • The most common side effects of LOQTORZI™ when used with cisplatin and gemcitabine include: nausea; vomiting; decreased appetite; constipation; low levels of thyroid hormone; rash; fever; diarrhea; burning or feeling of pins and needles in feet and toes; cough; muscle and bone pain; upper respiratory infection; sleep problems; dizziness; and feeling generally unwell.
  • The most common side effects of LOQTORZI™ when used alone include: tiredness; low levels of thyroid hormone; muscle and bone pain.

These are not all the possible side effects of LOQTORZI™. Talk to your health care provider for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please read the Medication Guide and Prescribing Information for LOQTORZI™.